From: A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy
Titers 14 days after initial immunization | ||||
---|---|---|---|---|
Mouse # | PSA + anti-PSA IgE | PSA + anti-PSA IgG1 | PSA | Buffer |
1 | 8,100 | 100 | 900 | 0 |
2 | 2,700 | 24,300 | 0 | 0 |
3 | 900 | 8,100 | 0 | 0 |
4 | 2,700 | 24,300 | 0 | 0 |
5 | 2,700 | 24,300 | 2,700 | 0 |
6 | 900 | 72,900 | 8,100 | 0 |
7 | 24,300 | 8,100 | 900 | 0 |
8 | 900 | 2,700 | 900 | 0 |
Median | 2,700 | 16,200 | 900 | 0 |
Titers 13 days after booster (28 days after initial immunization) | ||||
Mouse # | PSA + anti-PSA IgE | PSA + anti-PSA IgG1 | PSA | Buffer |
1 | 218,700 | 8,100 | 24,300 | 0 |
2 | 218,700 | 72,900 | 0 | 0 |
3 | 72,900 | 24,300 | 0 | 0 |
4 | 218,700 | 218,700 | 0 | 0 |
5 | 72,900 | 400,000 | 218,700 | 0 |
6 | 72,900 | 218,700 | 218,700 | 0 |
7 | 24,300 | 218,700 | 8,100 | 0 |
8 | 218,700 | 24,300 | 72,900 | 0 |
Median | 145,800 | 145,800 | 16,200 | 0 |